Nijmegen

• A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharma … Ended
  2023-506723-28-00 4 2025-03-20 Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episo
• Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Ended
  2024-511440-76-00 1 2025-03-20 Cutaneous Squamous Cell Carcinoma
• The sedative effects and local tolerability of nasal administration of remimazolam using a Soft Mist Nasal Administration Device Ended
  2024-516493-30-01 4 2025-03-10 stress anxiety
• Serotonin and decision-making Ended
  2024-516055-41-00 6 2025-03-06 None
• A Study to Understand the ability and safety of GDC-8264 in Preventing kidney Injury and Major Adverse Kidney Events following Heart Surgery Ended
  2024-513125-23-00 4 2025-02-28 Patients with moderate to high risk for cardiac surgery associated- ac
• GENPAD Ended
  2024-518122-33-00 6 2024-12-13 Peripheral Arterial Disease
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors Ended
  2022-502367-37-00 7 2024-11-29 Recurrent glioblastoma multiforme (GBM)
• TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents ag … Ended
  2024-515263-60-00 6 2024-11-22 SARS-CoV-2 infection
• rIFN-Gamma 1b in Candidemia Ended
  2024-510816-55-00 4 2024-11-08 Candidemia
• THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE … Ended
  2024-516260-29-00 5 2024-10-10 non-metastatic (borderline) resectable pancreatic cancer
• Study on PhArmacokiNetics of first liNe Antiretrovirals in healthy Breastfeeding volunteers or women living with HIV and already on antiretr … Ended
  2023-510232-36-00 3 2024-10-01 healthy breastfeeding women
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• Repeated corticosteroid injections around the Greater Occipital Nerve (GON) as prophylactic treatment in chronic cluster headache Ended
  2024-514311-10-00 5 2024-08-10 Cluster headache
• IPAD Trial Ended
  2024-513124-41-00 5 2024-07-12 Primary antibody deficiency: - Unclassified antibody deficiency (unPAD
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 4 2024-03-27 Neoplasm malignant
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A randomized double-blind placebo-controlled phase 1 study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single i … Ended
  2023-507035-37-00 1 2024-03-11 Circulatory shock
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• Ilofotase alfa for prevention of renal damage after cardiac surgery Ended
  2023-505859-45-00 4 2023-12-19 Risk for renal damage following open heart surgery
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 4 2023-11-15 Squamous cell carcinoma of head and neck

Showing 457–480 of 568 trials